Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy
| Autor: | Beatriz Roson, Arnaldo Casiro, Joan Albert Arnaiz, Xavier Badia, Irene Moral, Daniel Podzamczer, José M. Gatell, Montse Loncá, Montse Roset |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Anti-HIV Agents HIV Infections Indinavir Drug Administration Schedule Acquired immunodeficiency syndrome (AIDS) Quality of life Humans Medicine Pharmacology (medical) Sida Pharmacology Ritonavir biology business.industry HIV Protease Inhibitors Viral Load medicine.disease biology.organism_classification CD4 Lymphocyte Count Surgery Regimen Treatment Outcome Infectious Diseases HIV-1 Quality of Life Hiv patients Reverse Transcriptase Inhibitors Drug Therapy Combination Female Indinavir+Ritonavir business medicine.drug |
| Zdroj: | Antiviral Therapy. 9:979-985 |
| ISSN: | 2040-2058 1359-6535 |
| DOI: | 10.1177/135965350400900615 |
| Popis: | Objective To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. Methods Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly assigned to continue with this therapy or to change to a twice-daily indinavir/ritonavir (800/100 mg) regimen. The Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaire was used as the HRQoL measure. Results A total of 118 patients participated in the study, of which 59 (50%) were randomly assigned to continue with the three-times-daily regimen. Patients had a mean age of 39 years and 80% of them were male. At baseline, subjects included in the three-times-daily group presented a significantly greater number of symptoms than subjects in the twice-daily group, but no statistically significant differences were observed in MOS-HIV scores between the groups. In the intention-to-treat (ITT) analysis, a reduction in HRQoL scores was observed in both groups, which was greater in the twice-daily group. In the per protocol analysis, reduction of HRQoL was minimal. Conclusions A HRQoL deterioration, greater in the twice-daily group, was observed in this study in the ITT analysis, while HRQoL remained stable in both groups in patients who continued with and tolerated the allocated regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|